CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Long-Term Outcomes After Management of Restenosis or Thrombosis of Drug-Eluting Stents
Gregory J. Mishkel, MD, FACC*, , ,
Anna L. Moore, MPH,
Steve Markwell, MA,
M. Coleman Shelton and
Marc E. Shelton, MD, FACC*,,,*
* Prairie Heart Institute at St. John's Hospital, Springfield, Illinois
Prairie Education & Research Cooperative, Springfield, Illinois
Southern Illinois University School of Medicine, Springfield, Illinois
Manuscript received February 1, 2006;
revised manuscript received August 10, 2006,
accepted August 15, 2006.
* Reprint requests and correspondence: Dr. Marc E. Shelton, Prairie Cardiovascular Consultants, Ltd., Prairie Heart Institute, P.O. Box 19420, Springfield, Illinois 62794. (Email: mshelton{at}prairieheart.com).
OBJECTIVES: The purpose of this study was to examine the outcomes of patients who developed coronary in-stent restenosis (ISR) or stent thrombosis (STH) inside drug-eluting stents (DES).
BACKGROUND: Drug-eluting stents have markedly reduced the incidence of restenosis. However, when restenosis occurs within a DES, its optimal management remains unclear.
METHODS: We retrospectively analyzed clinical and angiographic data from 92 patients who underwent revascularization for ISR (n = 84) or STH (n = 8) within a DES at our institution. Regular follow-ups were available up to 2 years. We recorded the occurrence of major adverse cardiac events (MACE), defined as deaths from all causes, myocardial infarction (MI), or target lesion revascularization (TLR), among patients treated by the "DES sandwich" technique or by other treatment methods.
RESULTS: In-hospital MACE included 1 periprocedural MI and 2 deaths. Over a mean follow-up of 15 ± 6 months, the overall rates of death, MI, and TLR were 8.7%, 2.2%, and 30.6%, respectively. By actuarial analysis, the 12-month TLR and MACE rates were 28.2% and 42.9%, respectively.
CONCLUSIONS: Current treatments of ISR or STH in DES are associated with a high long-term rate of MACE.
|
Abbreviations and Acronyms
| | BMS = bare-metal stent(ing) | | DES = drug-eluting stents | | ISR = in-stent restenosis | | MACE = major adverse cardiovascular events | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | STEMI = ST-segment elevation myocardial infarction | | STH = stent thrombosis | | TLR = target lesion revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
I. Sheiban, D. Sillano, G. Biondi-Zoccai, A. Chieffo, A. Colombo, S. Vecchio, M. Margheri, J. P. Gunn, T. Raina, F. Liistro, et al.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study).
J. Am. Coll. Cardiol.,
September 22, 2009;
54(13):
1131 - 1136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The year in interventional cardiology.
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H Bhatt and T. H Hauser
Very Late Stent Thrombosis After Dual Antiplatelet Therapy Discontinuation in a Patient with a History of Acute Stent Thrombosis
Ann. Pharmacother.,
May 1, 2008;
42(5):
708 - 712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Harrington and E. M. Ohman
The Enigma of Drug-Eluting Stents: Hope, Hype, Humility, and Advancing Patient Care
JAMA,
May 9, 2007;
297(18):
2028 - 2030.
[Full Text]
[PDF]
|
|
|
|
